Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK.

Publication date: Apr 02, 2024

As mounting evidence suggests a higher incidence of adverse consequences, such as disruption of the immune system, among patients with a history of COVID-19, we aimed to investigate post-COVID-19 conditions on a comprehensive set of allergic diseases including asthma, allergic rhinitis, atopic dermatitis, and food allergy. We used nationwide claims-based cohorts in South Korea (K-CoV-N; n = 836,164; main cohort) and Japan (JMDC; n = 2,541,021; replication cohort A) and the UK Biobank cohort (UKB; n = 325,843; replication cohort B) after 1:5 propensity score matching. Among the 836,164 individuals in the main cohort (mean age, 50. 25 years [SD, 13. 86]; 372,914 [44. 6%] women), 147,824 were infected with SARS-CoV-2 during the follow-up period (2020-2021). The risk of developing allergic diseases, beyond the first 30 days of diagnosis of COVID-19, significantly increased (HR, 1. 20; 95% CI, 1. 13-1. 27), notably in asthma (HR, 2. 25; 95% CI, 1. 80-2. 83) and allergic rhinitis (HR, 1. 23; 95% CI, 1. 15-1. 32). This risk gradually decreased over time, but it persisted throughout the follow-up period (≥6 months). In addition, the risk increased with increasing severity of COVID-19. Notably, COVID-19 vaccination of at least two doses had a protective effect against subsequent allergic diseases (HR, 0. 81; 95% CI, 0. 68-0. 96). Similar findings were reported in the replication cohorts A and B. Although the potential for misclassification of pre-existing allergic conditions as incident diseases remains a limitation, ethnic diversity for evidence of incident allergic diseases in post-COVID-19 condition has been validated by utilizing multinational and independent population-based cohorts.

Open Access PDF

Concepts Keywords
Korea Allergic
Rhinitis Ci
Vaccines Cohort
Cohorts
Condition
Covid
Diseases
Hr
Incident
Korea
Multinational
Post
Replication
Risk
South

Semantics

Type Source Name
disease MESH COVID-19
pathway REACTOME Immune System
disease IDO history
disease MESH asthma
pathway KEGG Asthma
disease MESH allergic rhinitis
disease MESH atopic dermatitis
disease MESH food allergy
disease IDO replication
disease VO time
disease VO vaccination
disease VO population
disease MESH sequelae
drug DRUGBANK Coenzyme M
disease IDO infected population
disease MESH infection
disease VO vaccinated
disease MESH comorbidity
drug DRUGBANK Ethanol
disease VO age
disease MESH cardiovascular disease
disease MESH chronic kidney disease
disease MESH chronic obstructive pulmonary disease
disease MESH hyperlipidemia
disease MESH hypertension
disease MESH Underweight

Original Article

(Visited 1 times, 1 visits today)